

ANSWERING REVIEWERS

March 31th, 2016

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: main text reviewed 25386.doc).

Title: Reclassification of membranoproliferative glomerulonephritis (MPGN).

Identification of a new GN: C3GN

Authors: Maurizio Salvadori, Giuseppina Rosso

Name of the Journal: World Journal of Nephrology

ESPS Manuscript NO : 25386

The manuscript has been extensively reviewed according to the editor and reviewers suggestion.

1 Format has been updated and the English wording has been properly corrected by the American Journal Expert (please find certification enclosed); the conflict of interest has been provided, as well as the copyright assignment. Now you have a three colors manuscript (in black the original, in red the English rewording, in blue the modifications according the reviewers concerns)

2 Revision has been made according the suggestions of the reviewers, in particular:

Rev. 00503255

1. Abstract: The author cited the reference no.1 in the abstract. An abstract usually must not have any reference. Please delete it.

Response: The reference in the abstract has been deleted;

2. page 7, line 2: The author described “nephritic syndrome, acute nephritic syndrome”. Is “nephrotic syndrome, acute nephritic syndrome” right?

Response: Nephritic syndrome has been changed in nephritic syndrome

Rev. 00503252

1. It would be nice to mention newly developing treatment for the complement mediated MPGN if there are any.

Response: All the developing treatments for the complement mediated MPGN have been mentioned. Unfortunately they are few due to the causes mentioned in the manuscript.

2. GN-C3 in Figure 1 should be C3GN.

Response: GN-C3 in fig 1 has been modified in C3GN.

3. The phrase “many be formulated by” is duplicated (P11, L14).

Response: The phrase duplicated has been deleted.

Rev. 00503179

The paper comprises an in-depth review of membranoproliferative GN and especially the new classification from 2015. The previous classification is mentioned, but most of the paper deals with the new classification based on the presence of immunocomplexes, i.e. Ig-mediated (previous MPGN type I) or the presence of C3, but not immunocomplexes, i.e. C3-mediated (previous MPGN type II and III) and now DDD and GN-C3. The new classification is clearly explained. For IC associated MPGN, a rather short review is given including pathophysiology, clinical manifestations and therapy. For C3-mediated MPGN, a more extensive review is given including clinical signs, pathophysiology, diagnostic aspects and treatment. The review is balanced and stresses correctly the uncertainty regarding many aspects of these rare diseases. The treatment modalities are mentioned and discussed. Again, cautiousness is used in the evaluation of effect due to lack of RCTs. The reference list is extensive and relevant. To sum up, an excellent review regarding MPG and the new classification.

Response: Thank you for your comments. Nothing to add.

Rev. 00502999

1. The authors are Italian, and many words are translated literally from Italian to English. I am aware of this situation as I speak Spanish (which is ver very close to Italian) and Italian. For example, in page 3 authors state that MPGN and aHUS may be considered as PARENT diseases. This word PARENT workss in Italian and Spanish, but in English RELATED must be used.

Response: The English language has been completely reviewed by the American Journal Expert (the certification is enclosed). The word parents has been modified.

2. The paper is disorganized. The structure of the manuscript must be rewritten, as many parts are repeated.

Response: The paper has been partially rewritten and repeated parts have been deleted whenever possible.

3. The manuscript as a whole has to be shortened.

Response: The manuscript has been shortened as requested.



Maurizio SALVADORI MD

Dept of Transplantation

University of Florence

Viale Pieraccini 18

50139 Florence ITALY

Fax: +39-055-597151

Email: maurizio.salvadori1@gmail.com